Male Hypogonadism - Global Market Trajectory & Analytics

Description Table of
Contents

Global Male Hypogonadism Market to Reach $3.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Male Hypogonadism estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 2.9% over the period 2020-2027. Testosterone Replacement Therapy, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $830.8 Million, While China is Forecast to Grow at 2.8% CAGR

The Male Hypogonadism market in the U.S. is estimated at US$830.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$618.1 Million by the year 2027 trailing a CAGR of 2.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

Select Competitors (Total 47 Featured):

AbbVie, Inc.
Allergan PLC
AstraZeneca PLC
Bayer AG
Eli Lilly and Company
Endo International PLC
Ferring International Center SA
IBSA Institut Biochimique SA
Laboratoires Genevrier
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Topical Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Transdermal Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Other Drug Deliveries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Other Drug Deliveries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 22: USA Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 23: USA Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 24: USA 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 25: USA Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 26: USA Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 27: USA 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
CANADA
Table 28: Canada Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 29: Canada Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 30: Canada 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 31: Canada Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 32: Canada Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 33: Canada 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
JAPAN
Table 34: Japan Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 35: Japan Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 36: Japan 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 37: Japan Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Japan Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 39: Japan 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
CHINA
Table 40: China Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 41: China Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 42: China 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 43: China Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: China Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 45: China 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
EUROPE
Table 46: Europe Current & Future Analysis for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 47: Europe Historic Review for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 48: Europe 15-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Table 49: Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 50: Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 51: Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 52: Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 53: Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
FRANCE
Table 55: France Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 56: France Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 57: France 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 58: France Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 59: France Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 60: France 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
GERMANY
Table 61: Germany Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 62: Germany Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 63: Germany 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 64: Germany Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 65: Germany Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 66: Germany 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
ITALY
Table 67: Italy Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 68: Italy Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 69: Italy 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 70: Italy Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 71: Italy Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 72: Italy 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 73: UK Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 74: UK Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 75: UK 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 76: UK Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 77: UK Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 78: UK 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 79: Rest of Europe Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 80: Rest of Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 81: Rest of Europe 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 82: Rest of Europe Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 83: Rest of Europe Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 84: Rest of Europe 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 85: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 86: Asia-Pacific Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 87: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 88: Asia-Pacific Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 89: Asia-Pacific Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 90: Asia-Pacific 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027
REST OF WORLD
Table 91: Rest of World Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 92: Rest of World Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 93: Rest of World 15-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2012, 2020 & 2027
Table 94: Rest of World Current & Future Analysis for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 95: Rest of World Historic Review for Male Hypogonadism by Drug Delivery - Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 96: Rest of World 15-Year Perspective for Male Hypogonadism by Drug Delivery - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Deliveries for the Years 2012, 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 47

Note: Product cover images may vary from those shown

RELATED TAGS

RELATED PRODUCTS

Male Hypogonadism Market - Growth, Trends, and Forecast (2020 - 2025)

Human Chorionic Gonadotropin Market - Growth, Trends, and Forecasts (2020 - 2025)

Human Chorionic Gonadotropin Market - Growth, Trends, and Forecast (2020 - 2025)

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2020

Grain Mill Products Market by Product Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026